← Back to Clinical Trials
Recruiting NCT06609941

NCT06609941 Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06609941
Status Recruiting
Phase
Sponsor Foundation University Islamabad
Condition Bronchial Asthma
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2024-06-18
Primary Completion 2025-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Alternative nostril breathingPharmacological therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2024-06-18 with a primary completion date of 2025-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Eligibility Criteria

Inclusion Criteria: * Adults: aged (18-45 years) * Gender: Both males and females * Grade1- Grade 4 on Modified MRC dyspnea scale * Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin Exclusion Criteria: * Patients having acute exacerbation of COPD or status asthmaticus * Patients diagnosed with acute infections * Patients unable to follow command/ instructions * Asthma patients with \>40 sec control pause duration * Patients who fall in red zone of asthma action plan (PEFR \< 50%)

Contact & Investigator

Central Contact

Bazkha Tariq Aslam Khawaja, DPT

✉ bazkhatariq@gmail.com

📞 0333-1281293

Frequently Asked Questions

Who can join the NCT06609941 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Bronchial Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06609941 currently recruiting?

Yes, NCT06609941 is actively recruiting participants. Contact the research team at bazkhatariq@gmail.com for enrollment information.

Where is the NCT06609941 trial being conducted?

This trial is being conducted at Rawalpindi, Pakistan.

Who is sponsoring the NCT06609941 clinical trial?

NCT06609941 is sponsored by Foundation University Islamabad. The trial plans to enroll 32 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology